Imugene Limited

OTCPK:IUGN.F Stock Report

Market Cap: US$176.8m

Imugene Management

Management criteria checks 2/4

Imugene's CEO is Leslie Chong, appointed in Nov 2016, has a tenure of 8.08 years. total yearly compensation is A$2.50M, comprised of 31.2% salary and 68.8% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth $1.90M. The average tenure of the management team and the board of directors is 1.8 years and 6.2 years respectively.

Key information

Leslie Chong

Chief executive officer

AU$2.5m

Total compensation

CEO salary percentage31.2%
CEO tenure8.1yrs
CEO ownership1.1%
Management average tenure1.8yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Leslie Chong's remuneration changed compared to Imugene's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$2mAU$780k

-AU$150m

Mar 31 2024n/an/a

-AU$119m

Dec 31 2023n/an/a

-AU$89m

Sep 30 2023n/an/a

-AU$64m

Jun 30 2023AU$2mAU$750k

-AU$38m

Mar 31 2023n/an/a

-AU$39m

Dec 31 2022n/an/a

-AU$40m

Sep 30 2022n/an/a

-AU$39m

Jun 30 2022AU$1mAU$600k

-AU$38m

Mar 31 2022n/an/a

-AU$33m

Dec 31 2021n/an/a

-AU$27m

Sep 30 2021n/an/a

-AU$23m

Jun 30 2021AU$789kAU$408k

-AU$18m

Mar 31 2021n/an/a

-AU$15m

Dec 31 2020n/an/a

-AU$12m

Sep 30 2020n/an/a

-AU$11m

Jun 30 2020AU$733kAU$375k

-AU$11m

Mar 31 2020n/an/a

-AU$10m

Dec 31 2019n/an/a

-AU$9m

Sep 30 2019n/an/a

-AU$8m

Jun 30 2019AU$777kAU$350k

-AU$8m

Mar 31 2019n/an/a

-AU$7m

Dec 31 2018n/an/a

-AU$6m

Sep 30 2018n/an/a

-AU$5m

Jun 30 2018AU$403kAU$300k

-AU$4m

Compensation vs Market: Leslie's total compensation ($USD1.56M) is about average for companies of similar size in the US market ($USD1.41M).

Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.

CEO

Leslie Chong

8.1yrs

Tenure

AU$2,497,743

Compensation

Ms. Leslie Chong served as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020 until July 2023. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Hopper
Executive Chairman12.2yrsAU$491.35k5.5%
$ 9.7m
Leslie Chong
CEO, MD & Executive Director8.1yrsAU$2.50m1.07%
$ 1.9m
Michael Tonroe
CFO & Company Secretary2.3yrsAU$810.31kno data
Bradley Glover
Chief Operating Officer1.3yrsAU$1.75mno data
Joseph Woodard
Chief Medical Officer1.3yrsAU$1.39mno data
Ursula McCurry
Chief Clinical Operations Officer2.9yrsno datano data
John Byon
Senior Vice President of Clinical Development1.3yrsno datano data

1.8yrs

Average Tenure

57yo

Average Age

Experienced Management: IUGN.F's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Paul Hopper
Executive Chairman12.2yrsAU$491.35k5.5%
$ 9.7m
Leslie Chong
CEO, MD & Executive Director6.8yrsAU$2.50m1.07%
$ 1.9m
Kimberlee Drapkin
Non-Executive Director1.5yrsAU$92.40k0.0016%
$ 2.8k
Yuman Fong
Chair of Oncolytic Virotherapy Scientific Advisory Board5.1yrsno data0.30%
$ 531.9k
Neil Segal
Member of Scientific Advisory Board10.7yrsno datano data
Josep Tabernero Caturla
Member of Scientific Advisory Board6.2yrsno datano data
Yelena Janjigian
Scientific Advisory Board Member8.7yrsno datano data
Lesley Russell
Independent Non-Executive Director5.7yrsAU$114.50k0.27%
$ 481.0k
Peter Schmid
Member of Scientific Advisory Board7yrsno datano data
Tanios Bekaii-Saab
Member of Scientific Advisory Board6.3yrsno datano data
Pravin T. Kaumaya
Member of Scientific Advisory Board6.2yrsno datano data
Prasad Adusumilli
Member of Scientific Advisory Board5.1yrsno datano data

6.2yrs

Average Tenure

63yo

Average Age

Experienced Board: IUGN.F's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 16:25
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Imugene Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Hunter DiamondDiamond Equity Research LLC
Dennis HulmeEdison Investment Research